Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Biogen Inc.
Biogen Inc. News
Biogen Inc. Quantitative Score
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Biogen Inc. Earnings & Revenue
Biogen Inc. Financials
Table Compare
Compare BIIB metrics with: | |||
|---|---|---|---|
Earnings & Growth | BIIB | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BIIB | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BIIB | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BIIB | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Biogen Inc. Income
Biogen Inc. Balance Sheet
Biogen Inc. Cash Flow
Biogen Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Biogen Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Biogen Inc. Executives
| Name | Role |
|---|---|
| Mr. Christopher A. Viehbacher | President, Chief Executive Officer & Director |
| Mr. Michael R. McDonnell CPA | Executive Vice President & Chief Financial Officer |
| Ms. Susan H. Alexander Esq. | Executive Vice President & Chief Legal Officer |
| Dr. Ginger Gregory Ph.D. | Executive Vice President & Chief Human Resources Officer |
| Ms. Nicole Murphy | Head of Pharmaceutical Operations & Technology |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Christopher A. Viehbacher | President, Chief Executive Officer & Director | Male | 1961 | 4.07M |
| Mr. Michael R. McDonnell CPA | Executive Vice President & Chief Financial Officer | Male | 1964 | 2.21M |
| Ms. Susan H. Alexander Esq. | Executive Vice President & Chief Legal Officer | Female | 1957 | 1.95M |
| Dr. Ginger Gregory Ph.D. | Executive Vice President & Chief Human Resources Officer | 1968 | 1.59M | |
| Ms. Nicole Murphy | Head of Pharmaceutical Operations & Technology | Female | 1973 | 1.45M |
Biogen Inc. Insider Trades
| Date | 30 Aug |
| Name | Singhal Priya |
| Role | Head of Development |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 1668 |
| Date | 30 Aug |
| Name | Singhal Priya |
| Role | Head of Development |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 807 |
| Date | 3 Sep |
| Name | Singhal Priya |
| Role | Head of Development |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 431 |
| Date | 30 Aug |
| Name | Singhal Priya |
| Role | Head of Development |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 1668 |
| Date | 21 Jun |
| Name | SHERWIN STEPHEN A |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 1340 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 30 Aug | Singhal Priya | Head of Development | Acquired | M-Exempt | 1668 |
| 30 Aug | Singhal Priya | Head of Development | Disposed | F-InKind | 807 |
| 3 Sep | Singhal Priya | Head of Development | Disposed | S-Sale | 431 |
| 30 Aug | Singhal Priya | Head of Development | Disposed | M-Exempt | 1668 |
| 21 Jun | SHERWIN STEPHEN A | Director | Acquired | A-Award | 1340 |